The New Generation of Digital Therapeutics
September 16, 2021
11:00 AM – 12:15 PM
Held virtually due to COVID-19
11:00-12:00 PM Session
"The New Generation of Digital Therapeutics"
A new class of digital therapeutics is advancing beyond prior generations’ focus on tracking adherence and digitizing behavioral therapy. It is now advancing towards the first-ever class of digital treatments that engage targets of disease to positively alter the course of treatment via drug-like mechanisms of action. Among these new therapeutic interventions are emerging treatments that leverage translational medicine and validated biomarkers to affect disease modification of chronic and debilitating conditions.
These next-generation digital therapeutics can demonstrate their potential via translationally validated mechanisms of action that positively change both structure and function in high impact, unmet needs including Alzheimer’s, Multiple Sclerosis, stroke recovery, and cognition. Given the capacity of these therapeutics to delay or change the trajectory of disease progression, a new emerging class of digital treatments emphasizes the significant value for health plans, patients, and providers.
(The 17th Forum is hosted by W Medical Strategy Group and supported by Korea Health Industry Development Institute (KHIDI) and WR Regulatory Services.)
Kimberly Ha, Moderator | CEO and Founder, KKH Advisors | WAMJ Editorial Board Member
Edward Cox, | EVP Strategic Alliances & Global Head of Digital Medicine, Eversana
Brian Harris | CEO and Co-Founder, MedRhythms Inc.
Eddie Martucci, PhD | CEO and Co-Founder, Akili Interactive
Joseph McMenamin, MD, JD | EVP, W Medical Strategy Group
Brent Vaughan | CEO, Cognito Therapeutics
Moderator: Kimberly Ha
CEO and Founder, KKH Advisors | WAMJ Editorial Board Member
Kimberly Ha is the founder and CEO of KKH Advisors, a life sciences strategic communications advisory firm. She was previously Senior Director at FTI Consulting, Healthcare Capital Markets Communications, where she advised a broad range of clients from Fortune 500 to early-stage development companies on business transformation, corporate and executive positioning, crisis and issues management, and financial communications. She is a digital health advisor at UCSF Health Hub, Springboard Enterprises, and a Limited Partner at Array Ventures, a SF-based tech VC fund.
EVP Strategic Alliances & Global Health of Digital Medicine | Eversana
Eward is a respected a thought leader in the digital therapeutics sector, having built a foundation for the entire industry that allowed hundreds of companies to follow. He is uniquely positioned to lead digital medicine companies and initiatives in this rapidly expanding space: He has background in executive leadership across numerous industries including pharma and biotech, technology, investment banking, and public markets. He led Dthera Sciences as CEO from inception into a pioneering Digital Therapeutics company that was granted FDA Breakthrough Device designation for the treatment of Alzheimer’s disease and recognized as a top 10 company in the Digital Therapeutics sector. He has been asked to serve highly visible roles at the most prominent events in the digital medicine space including serving as chair at DTx Europe, and DTx West and East. He excels at finding creative and asymmetric pathways to drive success from business development to commercial launch. He adept at investor relations, corporate development and building high profile strategic partnerships.
CEO and Co-Founder, MedRhythms, Inc.
Brian is the CEO and co-founder of MedRhythms. He is passionate, motivated, and committed to bringing high-quality care to everyone who needs it. This vision inspired the creation of MedRhythms and has allowed the company to expand and evolve to better serve patients. In 2011, Brian completed his undergraduate degree in Psychology at the University of Maine and went on to receive his masters in Music Therapy. After completing his masters, Brian continued to expand his knowledge and experience in the field, ultimately becoming a Board-Certified Music Therapist with specialized training in Neurologic Music Therapy (NMT). He later received advanced training in the field, becoming one of only 350 people in the world with the distinction of NMT Fellow. Harris was hired as the first NMT at Spaulding Rehabilitation Hospital in Boston, where, in 2015, he founded the clinical division of MedRhythms focusing on stroke, brain injury, and neurologic disease. With his continued leadership, the therapy practice has grown into the most comprehensive NMT program in the country.
Eddie Martucci, PhD
CEO and Co-Founder, Akili Interactive
Eddie co-founded Akili Interactive, and as part of PureTech has co-founded two other health-focused start-ups, and helped launch their digital health initiative. He was previously a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation of Kansas City, MO, focused on healthcare entrepreneurship. Prior to that, he completed his graduate work at Yale University in the Departments of Pharmacology and Molecular Biophysics & Biochemistry, focusing on structure-based drug design, where he led a research project that identified two novel chemical scaffolds as proof-of-concept compounds for novel therapy. Eddie received his B.S. in Biochemistry from Providence College, and his M.Phil. and Ph.D. from Yale University. Eddie frequently serves on discussion panels for industry and academic events related to healthcare innovation, has appeared in media including CNN's Vital Signs with Sanjay Gupta, and Akili has received recognition including the 2014 Future of Health Technology product award, 2015 50-on-Fire Boston, and the #1 health company in Entrepreneur magazine's 100 Brilliant Companies of 2016.
Joseph McMenamin, MD, JD
EVP, W Medical Strategy Group
Joseph (Joe) P. McMenamin is an Executive Vice President and Chief Legal Officer with W Medical Strategy Group. He has more than 20 years of experience in defending pharmaceutical, medical device, and biotech companies in state and federal court. He also advises clients on managing risks related to telemedicine, corporate use of the internet, social media, communications between life science companies and physicians, compliance with FDA regulations.
CEO, Cognito Therapeutics
Brent Vaughan is CEO of Cognito Therapeutics, a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders including Alzheimer’s disease. With more than 20 years of experience, he has a proven track record of success developing proprietary technologies and products across multiple domains, including digital therapeutics, medical devices and pharmaceuticals. Prior to Cognito, Brent was Chief Executive Officer and Co-Founder at Cognoa, an AI-based digital therapeutics company, where he established the company as a leader in digital therapeutics and pediatric behavioral health. Under his leadership, Cognoa was awarded FDA Breakthrough Designation for the first two products for autism and successfully completed the clinical development of the lead product. He was also co-founder at WellnessFX, a leading digital health company. Brent has also held leadership positions in business development and product management in therapeutic and medical device companies including Saegis Pharmaceuticals, Nektar Therapeutics, and Roche. He received his M.B.A. from Santa Clara University and a B.S. in Biochemistry from the University of California, Davis.